Interleukin 1 Receptor Antagonist Inhibits Localized Bone Formation in Vivo

Journal of Rheumatology

Volumn 30, Issue 12, 2003, Pages 2547-2552

  Ma, Ting ^a   Miyanishi, Keita ^a   Trindade, Michael C D ^a   Genovese, Mark ^b   Regula, Donald ^a   Smith, R Lane ^a   Goodman, Stuart B ^a,c  

^a Department of Orthopaedic Surgery ^*

^b Shelby Biomedical Research Building 302   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone formation; Interleukin 1 receptor antagonist

Indexed keywords

BOVINE SERUM ALBUMIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; CONTROLLED STUDY; DEVICE; DRUG INFUSION; DRUG TEST CHAMBER; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMPLANT; IN VIVO STUDY; MALE; NONHUMAN; OSMOTIC PUMP; OSSIFICATION; PRIORITY JOURNAL; RABBIT; TISSUE DIFFERENTIATION; TISSUE GROWTH;

ACID PHOSPHATASE; ANIMALS; IMMUNOENZYME TECHNIQUES; INFUSION PUMPS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ISOENZYMES; MALE; OSTEOCLASTS; OSTEOGENESIS; RABBITS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; TIBIA;

EID: 0346848793     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mantovani A. The interleukin-1 system. In: Theze J, editor. The cytokine network and immune functions. New York: Oxford University Press; 1999:85-96.
2. Tocci M, Schmidt J. Interleukin-1: structure and function. In: Remick D, Friedland J, editors. Cytokines in health and disease. New York: Marcel Dekker; 1997:1-28.
3. Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russell RGG. An interleukin-1-like factor stimulates bone resorption in vitro. Nature 1983;306:378-80.
4. Skjodt H, Russell G. Bone cell biology and the regulation of bone metabolism. In: Gown M, editor. Cytokines and bone metabolism. Boca Raton: CRC Press; 1990:1-70.
5. Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-67.
6. Stashenko P, Dewhirst FE, Peros WJ, Kent RL. Synergistic interaction between IL-1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987;138:1464-8.
7. Kon T, Cho TJ, Alzawa T, et al. Expression of osteoprotegerin, receptor activator of NF-kB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 2001;16:1004-14.
8. al Saffar N, Revell PA. Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: a potential role in osteolysis. Br J Rheumatol 1994;33:309-16.
9. Dayer JM, Feige U, Edwards CK III, Burger D. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001;13:170-6.
10. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 receptor antagonist binds to the 80 kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991;266:10331-6.
11. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to type II interleukin-1 receptor. J Biol Chem 1991;266:14147-50.
12. Seckinger P, Jenneke KN, Alander C, Thompson RC, Dayer JM, Raisz LG. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990;145:4181-4.
13. 2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin-1 and inhibitor(s). J Clin Invest 1986;78:1120-4.
14. Arend WP, Joslin FG, Massoni RG. Effects of immune complexes on production by human monocytes of interleukin-1 or an interleukin-1 inhibitor. J Immunol 1985;134:3868-75.
15. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991;266:14147-50.
16. Opal SM. Interleukin-1 receptor antagonist. In: Henderson B, Bodmer MW, editors. The therapeutic modulation of cytokines. Boca Raton: CRC Press; 1996:198-219.
17. Ma Y, Thornton S, Bovin GP, Hursh D, Hirsch R, Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:1798-805.
18. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999;42:498-506.
19. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1ra. Arthritis Rheum 1996;39:797-809.
20. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001;30:1-6.
21. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier. RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.
22. Probst A, Spiegel HU. Cellular mechanisms of bone repair. J Invest Surg 1997;10:77-86.
23. Aspenberg P, Albrektsson T, Lohmander LS, Thorngren KG. Drug test chamber: a titanium implant for administration of biochemical agents to a standardized bone callus in situ. J Biomed Eng 1988;10:70-3.
24. Goodman SB, Trindade MC, Ma T, et al. Modulation of bone ingrowth and tissue differentiation by local infusion of IL-10 in the presence of UHMWPE wear particles. J Biomed Mater Res 2003;65A:43-50.
25. Chun L, Yoon J, Song Y, Huie P, Regula D, Goodman SB. The characterization of macrophages and osteoclasts in tissues harvested from revised total hip prostheses. J Biomed Mater Res 1999;48:899-903.
26. Goodman SB, Song Y, Chun L, Aspenberg P, Regula D. Effects of TGFβ on bone ingrowth in the presence of polyethylene particles. J Bone Joint Surg Br 1999;81:1069-75.
27. Goodman S, Ma T, Trindade MC, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 2002;20:1164-9.
28. Feige U, Hu YL, Gasser J, Campagnulo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000;57:1457-70.
29. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16:457-99.
30. Lewthwaite J, Blake S, Thompson RC, Hardingham TE, Henderson B. Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis. Ann Rheum Dis 1995;54:591-6.
31. Amer EC, Harris RR, DiMeo TM, Collins RC, Galbraith W. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. J Rheumatol 1995;22:1338-46.
32. Leibovich SJ, Olsen CE, Graham MF, et al. Inflammation and wound healing. In: Hunt TK, Heppenstall RB, Pines E, Rovee D, editors. Soft and hard tissue repair. New York: Preager Publishers-CBS Educational and Professional Publishing; 1984:329-80.
33. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999;7:419-21.
34. Simon AM, Manigrasso MB, O'Connor P. Cyclo-Oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.
35. Trindade MC, Song Y, Aspenberg P, Smith RL, Goodman SB. Proinflammatory mediator release in response to particle challenge: Studies using the bone harvest chamber. J Biomed Mater Res 1999;48:434-9.
36. Chandrasekhar S, Panetta JA, Bendele AM. Inhibition of IL-1 induced articular inflammation of rats by 4-aminothiazolidines, LY 221068 and LY 269415. Agents Actions 1994;42:67-70.
37. Iwaki A, Jingushi S, Oda Y, et al. Localization and quantification of proliferating cells during rat fracture repair: detection of proliferating cell nuclear antigen by immunohistochemistry. J Bone Miner Res 1997;12:96-102.
38. Nakase T, Takaoka K, Masuhara K, Shimizu K, Yashikawa H, Ochi T. Interleukin-1β enhances and tumor necrosis factor-α inhibits bone morphogenetic protein-1-induced alkaline phosphatase activity in MC3T3-E1 osteoblastic cells. Bone 1997;21:17-21.
39. Hu DE, Hori Y, Presta M, Gresham GA, Fan TP. Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation 1994;18:45-58.
40. Libby P, Wyler DJ, Janicka MW, Dinarello CA. Differential effects of human interleukin-1 on growth of human fibroblasts and vascular smooth muscle cells. Arteriosclerosis 1985;5:186-91.